Spyre Therapeutics (SYRE) Stock Overview
A clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
SYRE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Spyre Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.24 |
| 52 Week High | US$40.26 |
| 52 Week Low | US$10.91 |
| Beta | 2.91 |
| 1 Month Change | 50.07% |
| 3 Month Change | 36.53% |
| 1 Year Change | -32.11% |
| 3 Year Change | 85.29% |
| 5 Year Change | -88.92% |
| Change since IPO | -92.58% |
Recent News & Updates
Intelligent Development Could Make Spyre Therapeutics Best In Show
Sep 19Companies Like Spyre Therapeutics (NASDAQ:SYRE) Are In A Position To Invest In Growth
Jul 15
Recent updates
Intelligent Development Could Make Spyre Therapeutics Best In Show
Sep 19Companies Like Spyre Therapeutics (NASDAQ:SYRE) Are In A Position To Invest In Growth
Jul 15Spyre Therapeutics: Targeting The Future Of IBD Treatment
Mar 04Spyre Therapeutics: Different Name, Same Tune
Dec 12Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting
Oct 01Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely
Feb 24We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate
Oct 28Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase
Aug 18Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M
Aug 04Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?
Jun 09Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower
Dec 07Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts
Aug 10Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 08Shareholder Returns
| SYRE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.1% | 0.9% | -1.2% |
| 1Y | -32.1% | -0.6% | 15.1% |
Return vs Industry: SYRE underperformed the US Biotechs industry which returned -0.6% over the past year.
Return vs Market: SYRE underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| SYRE volatility | |
|---|---|
| SYRE Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SYRE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SYRE's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 87 | Cameron Turtle | www.spyre.com |
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies.
Spyre Therapeutics, Inc. Fundamentals Summary
| SYRE fundamental statistics | |
|---|---|
| Market cap | US$1.34b |
| Earnings (TTM) | -US$161.72m |
| Revenue (TTM) | n/a |
Is SYRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYRE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$176.99m |
| Gross Profit | -US$176.99m |
| Other Expenses | -US$15.27m |
| Earnings | -US$161.72m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SYRE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 22:02 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spyre Therapeutics, Inc. is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Mayur Somaiya | BMO Capital Markets Equity Research |
| Julian Harrison | BTIG |